FIELD: medicine.
SUBSTANCE: proposed group of inventions relates to medicine. Method and a system for evaluating the efficacy of drug candidates selected from a group of drug candidates for a physiological process are disclosed. Method involves obtaining data from samples in which said physiological process takes place, and from control samples in which said physiological process does not occur, determining a set of genes or their products and signalling pathways statistically significantly activated or inhibited in samples in which said physiological process, as compared to control samples, determining a set of genes and signalling pathways after exposure of each drug candidate selected from a group of drug candidates to cells or biological tissues in which said physiological process can occur, and determining efficacy values for said physiological process for each drug candidate.
EFFECT: proposed group of inventions provides a more effective method of assessing the effectiveness of drug candidates for a physiological process.
3 cl, 7 dwg, 3 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
ONCOBOX GENETIC INFORMATION ANALYSIS PLATFORM | 2018 |
|
RU2741703C1 |
METHOD OF SEARCHING FOR THERAPEUTICALLY SIGNIFICANT MOLECULAR TARGETS FOR DISEASES BY APPLYING MACHINE LEARNING METHODS TO COMBINED DATA INCLUDING SIGNALING PATHWAY GRAPHS, OMIX AND TEXT DATA TYPES | 2022 |
|
RU2798897C1 |
METHOD FOR SEARCHING TARGET PROTEINS TRIGGERING PROCESS OF CARCINOGENESIS, IN INDIVIDUAL PATIENT'S TISSUE SAMPLES FOR PURPOSES OF SUBSEQUENT ANTITUMOUR MEDICINAL TREATMENT | 2013 |
|
RU2577107C2 |
METHOD OF CREATING TARGET PANEL FOR STUDYING GENOMIC REGIONS FOR DETECTING THERAPEUTIC BIOMARKERS OF IMMUNE CHECKPOINT (IC) INHIBITORS | 2023 |
|
RU2818360C1 |
SELECTION OF CANCER PATIENTS FOR INTRODUCTION OF WNT SIGNAL INHIBITORS BASED ON RNF43 MUTATION STATUS | 2013 |
|
RU2636000C2 |
SYSTEM FOR SIMULATING MOLECULAR INTERACTIONS INVOLVED IN THE INFLAMMATORY PROCESS | 2020 |
|
RU2804998C2 |
BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS | 2013 |
|
RU2659173C2 |
BIOMARKERS FOR THERAPY, BASED ON HEDGEHOG INHIBITOR | 2012 |
|
RU2602185C2 |
METHOD OF USING AXL AS MARKER OF EPITHELIAL-MESENCHYMAL TRANSITION | 2010 |
|
RU2586493C2 |
MICRORNA-124 AS BIOMARKER | 2014 |
|
RU2687366C2 |
Authors
Dates
2019-10-21—Published
2018-06-09—Filed